Detalles de la búsqueda
1.
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood
; 136(7): 823-830, 2020 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32496541
2.
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Lancet Oncol
; 19(12): 1668-1679, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30442503
3.
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Biol Blood Marrow Transplant
; 23(9): 1491-1497, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28527985
4.
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).
Br J Haematol
; 175(5): 917-924, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27714772
5.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol
; 16(16): 1691-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26549589
6.
EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.
Haematologica
; 105(5): e228-e231, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31413097
7.
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
Lancet
; 380(9850): 1309-16, 2012 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-22877506
8.
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.
Blood Cancer J
; 13(1): 18, 2023 01 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36693840
9.
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Leukemia
; 37(12): 2395-2403, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37833543
10.
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
J Cancer Res Clin Oncol
; 148(5): 1171-1181, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34176014
11.
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Leukemia
; 36(10): 2519-2527, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36071100
12.
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.
J Hematol Oncol
; 15(1): 60, 2022 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35562747
13.
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.
Cancers (Basel)
; 13(9)2021 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33926021
14.
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Blood Adv
; 5(17): 3279-3289, 2021 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34459887
15.
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Leukemia
; 35(9): 2517-2525, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33603142
16.
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Blood Adv
; 4(13): 3085-3092, 2020 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32634236
17.
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.
Blood Adv
; 4(13): 3093-3101, 2020 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32634237
18.
Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median followup of 14.4 years.
J Cancer Res Clin Oncol
; 149(2): 929-931, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36083312
19.
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Clin Lymphoma Myeloma Leuk
; 18(4): 266-271, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29510895
Resultados
1 -
19
de 19
1
Próxima >
>>